Project Grant R01AI192197
Award Date 8/8/25
Completion Date 7/31/29
Dollars Obligated $3M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,379,954 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute. The grant, awarded on August 21, 2025, supports research to engineer durable immunity by optimizing HIV vaccine parameters to drive long-lived plasma cell development. The project aims to systematically study the effects of immunogen affinity, valency, adjuvants, vaccine platforms, and...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $910,905 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute in La Jolla, CA. The grant, awarded on July 1, 2025, supports the development of an HIV vaccine using a lipid nanodisc platform to incorporate the envelope (Env) glycoprotein of HIV. The project aims to enable scalable and reproducible in vitro characterization and optimization of engineered...
- This Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $1,285,304 to the Scripps Research Institute to conduct research on developing a durable broadly neutralizing antibody (bnAb) response for an HIV vaccine. The key objectives are to: Assess the durability of a 6-shot sequential vaccine regimen that induces bnAb responses in non-human primates. Evaluate the...
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $108,486 to the Scripps Research Institute to develop soluble and membrane-bound immunogens that can shepherd the maturation of broadly neutralizing antibodies (bnAbs) targeting the highly conserved membrane proximal external region (MPER) of the HIV-1 envelope protein. The goal is to advance the quest for a...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $859,992 Project Grant to Yale University for the "Molecular Investigations of HIV-1 Maturation Pathways and Inhibitor Actions in situ" research project. The grant, funded under NIAID's Allergy and Infectious Diseases Research Program (CFDA 93.855), aims to use advanced in-situ cryo-electron microscopy and tomography techniques to visualize the structural transitions of the HIV-1 virus during the maturation...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $883,119 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute to develop a novel mRNA vaccine and immunotherapy against hepatitis B virus (HBV) infection. The award supports research to investigate viral and cellular factors that hinder effective antigen expression and improve vaccine antigens to elicit potent antibody and T cell responses to cure HBV...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $230,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute to develop a broad-spectrum influenza vaccine. The project aims to evaluate recently discovered neuraminidase broadly neutralizing antibodies (NA BNAbs) and engineer NA immunogens that can engage diverse BNAb precursors, a strategy called germline targeting. This protein engineering effort...
- The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded $852,121.24 to The Scripps Research Institute-Florida under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period of July 22, 2021 through October 31, 2021. The project aims to identify host factors that regulate HIV latency and reactivation in order to develop strategies for durable HIV silencing. The grantee will define the roles of three identified host factors, P32,...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,275,484 Cooperative Agreement to Weill Medical College of Cornell University on August 12, 2025 under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855). The goal of this project is to identify an optimal prime-boost immunization strategy to guide antibody maturation towards broad neutralization of HIV in early life. The project aims to: 1) Compare sequential versus simultaneous...
- The National Institute of Allergy and Infectious Diseases (NIAID), through the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $999,991 Project Grant to Tendel Therapies Inc. on August 13, 2025. The grant supports the development of an HIV reservoir-depletion agent, BSAB-98, a bispecific antibody that targets CCR5-expressing cells for elimination. Preclinical studies in infant rhesus macaques showed over 50% remission of simian immunodeficiency virus (SIV) after BSAB-98...